Cognito Therapeutics has presented groundbreaking clinical data at the Alzheimer’s Association International Conference (AAIC) 2021, demonstrating the disease-modifying effects of gamma frequency neuro-modulation on Alzheimer’s disease.
According to a press release from BioSpace, the clinical data highlights the remarkable impact of gamma frequency neuro-modulation on cognitive function and brain atrophy in Alzheimer’s patients. The study provides compelling evidence of the therapy’s potential to modify the course of Alzheimer’s disease, addressing both cognitive decline and structural brain changes.
The research builds upon previous studies indicating the therapeutic benefits of gamma frequency neuro-modulation. By targeting neural oscillations associated with memory and cognitive function, the therapy aims to restore brain activity and counteract the pathological processes underlying Alzheimer’s disease.
To read the full article, continue here.
